Headlines about Cellectis (NASDAQ:CLLS) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellectis earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.338688523006 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s analysis:
- Cellectis S.A. (CLLS) Receives “Hold” Rating from SunTrust Banks, Inc. (americanbankingnews.com)
- Cellectis SA Gets a Hold Rating from SunTrust Robinson $CLLS https://t.co/3BWwuXm1Qe (4-traders.com)
- Zoetis Inc. (ZTS) has a value of $63.57 per share While Cellectis SA (CLLS) is stand at $29.12 – Stocks Gallery (stocksgallery.com)
- Mathieu Simon, M.D. Cellectis’ EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer (finance.yahoo.com)
Shares of Cellectis (NASDAQ CLLS) opened at 29.54 on Thursday. Cellectis has a 52 week low of $16.09 and a 52 week high of $32.46. The firm’s market cap is $1.06 billion. The firm has a 50-day moving average of $28.13 and a 200 day moving average of $28.13.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
What are top analysts saying about Cellectis S.A.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cellectis S.A. and related companies.